| Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. | |
| | |
MedLine Citation:
|
PMID: 18710748 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: Groups have investigated time to testosterone recovery in patients who have undergone androgen deprivation therapy, usually by measuring androgen every 3 months, with varying results. To our knowledge this represents the largest study using monthly testosterone and dihydroxytestosterone measurement to evaluate the kinetics of androgen recovery following limited androgen deprivation therapy. MATERIALS AND METHODS: Monthly serum androgen levels were analyzed following 2, 6-month cycles of gonadotropin-releasing hormone agonist therapy as part of a randomized, placebo controlled study of the role of thalidomide in delaying time to prostate specific androgen progression. RESULTS: By the Kaplan-Meier method the median time to testosterone normalization in cycles 1 vs 2 was 15.4 vs 18.3 weeks with similar dihydroxytestosterone recovery times. Neither on-study prostate specific antigen, Gleason score nor thalidomide treatment had a significant impact on time to testosterone normalization. However, in cycle 1 men with low baseline dihydroxytestosterone and those who were more than 67 years old had significantly longer time to T normalization on Cox model analysis. Additionally, in cycle 2 patients with prior local radiation therapy had longer time to testosterone normalization, although this was no longer significant on Cox model analysis. Cox model analysis in cycle 2 showed that low baseline dihydroxytestosterone and testosterone, low testosterone nadir and white race were associated with longer time to testosterone normalization. CONCLUSIONS: Findings of delayed testosterone recovery may be useful for designing and analyzing clinical trials of limited androgen deprivation therapy and for estimating the duration of treatment associated side effects in patients undergoing limited androgen deprivation therapy. |
| | |
Authors:
|
James L Gulley; Jeanny B Aragon-Ching; Seth M Steinberg; Maha H Hussain; Oliver Sartor; Celestia S Higano; Daniel P Petrylak; Gurkamal S Chatta; Philip M Arlen; William D Figg; William L Dahut |
Related Documents
:
|
7509528 - Second-generation delivery systems for laser prostatic ablation. 2444308 - The efficacy of bromocriptine in benign prostatic hypertrophy. a double-blind study. 9787978 - Efficacy and acceptability of tadenan (pygeum africanum extract) in the treatment of be... 12322948 - Operational note indoor low-volume spray trials: handheld equipment evaluation. 9821828 - Echinacea root extracts for the prevention of upper respiratory tract infections: a dou... 21227948 - Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide and propafen... |
Publication Detail:
|
Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural Date: 2008-08-16 |
Journal Detail:
|
Title: The Journal of urology Volume: 180 ISSN: 1527-3792 ISO Abbreviation: J. Urol. Publication Date: 2008 Oct |
Date Detail:
|
Created Date: 2008-09-12 Completed Date: 2008-09-30 Revised Date: 2012-03-07 |
Medline Journal Info:
|
Nlm Unique ID: 0376374 Medline TA: J Urol Country: United States |
Other Details:
|
Languages: eng Pagination: 1432-7; discussion 1437 Citation Subset: AIM; IM |
Affiliation:
|
Center for Cancer Research, Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland 20892, USA. gulleyj@mail.nih.gov |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Androgen Antagonists / therapeutic use* Androgens / blood*, metabolism Antineoplastic Agents, Hormonal / therapeutic use* Biopsy, Needle Dose-Response Relationship, Drug Drug Administration Schedule Follow-Up Studies Goserelin / therapeutic use Humans Immunohistochemistry Leuprolide / therapeutic use Male Middle Aged Neoplasm Staging Probability Prospective Studies Prostate-Specific Antigen / blood Prostatic Neoplasms / drug therapy*, pathology* Recovery of Function Reference Values Risk Assessment Testosterone / blood*, metabolism Thalidomide / therapeutic use Treatment Outcome |
| Grant Support | |
ID/Acronym/Agency:
|
NIH0011802535//PHS HHS; Z99 CA999999/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Androgen Antagonists; 0/Androgens; 0/Antineoplastic Agents, Hormonal; 50-35-1/Thalidomide; 53714-56-0/Leuprolide; 58-22-0/Testosterone; 65807-02-5/Goserelin; EC 3.4.21.77/Prostate-Specific Antigen |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Is varicocele associated with underlying venous abnormalities? Varicocele and the prostatic venous p...
Next Document: A novel technique for creating solid renal pseudotumors and renal vein-inferior vena caval pseudothr...